Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis
These findings suggest that PMF patients with a JAK2 mutation have a higher PD-L1 expression in megakaryocytes compared with the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD-L1 expression.
Authors
- Nakhle S. Saba (ORCID: https://orcid.org/0000-0003-3206-2575)
- Janet Schmid
- Matthew Mastrodomenico
- Moayed Ibrahim (ORCID: https://orcid.org/0000-0003-0355-2380)
- Catherine R. Murphree (ORCID: https://orcid.org/0000-0003-0893-1419)
- Francisco Socola (ORCID: https://orcid.org/0000-0002-4002-9284)
- Hana Safah
- Kirtesh R. Patel
Institutions
- Tulane University (US)
- Delta Air Lines (United States) (US)
- Tulane Medical Center (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cnr2.2054
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44